Drug Profile


Alternative Names: JNJ-27018966; Mu Delta; TRUBERZI; VIBERZI

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Allergan
  • Class Amides; Benzoic acids; Imidazoles; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Opioid delta receptor antagonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Irritable bowel syndrome

Most Recent Events

  • 09 Nov 2017 Allergan plans a phase II trial for Irritable Bowel Syndrome (In Children) in USA, Bulgaria, Canada, Poland (NCT03339128)
  • 27 Jul 2017 The National Institute of Health and Care Excellence recommends availability of eluxadoline on the National Health Service for adult patients with Irritable bowel syndrome with diarrhoea
  • 26 Jul 2017 NICE expects to publish the final guidance for eluxadoline in Irritable bowel syndrome with diarrhoea at the end of August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top